Yasemin M. Akay

Yasemin M. Akay received the B.S. degree in pharmaceutical sciences from Hacettepe University, Ankara, Turkey, in 1980, and the M.S. and Ph.D. degrees in biomedical engineering from Rutgers University, Piscataway, NJ, USA, in 1991 and 1998, respectively. She was a Post-Doctoral Fellow with the Physiology Department and the Pharmacology Department, Dartmouth Medical School, and the Department of Physiology and Biophysics, School of Medicine, Boston University. She is currently an Instructional and Research Assistant Professor with the Department of Biomedical Engineering, Cullen College of Engineering, University of Houston. Her current research interests include molecular neuroengineering, neural growth, and neurodegeneration. She was an Assistant Editor of the IEEE Book Series from 2001 to 2004, and has been the Managing Editor of the Wiley Encyclopedia of Biomedical Engineering since 2004.

Associated articles

JTEHM, Articles, Published Articles
Engineering a High-Throughput 3D in vitro Glioblastoma Model
Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor in adults. The existing treatment for GBM, which involves a combination of resection, chemotherapy and radiotherapy, has a very limited success rate with a median survival rate of... Read more
JTEHM, Articles, Published Articles
The Assessment of Stent Effectiveness Using a Wearable Beamforming MEMS Microphone Array System
Studies involving turbulent flow have been carried out in many parts of the cardiovascular system, and it has been widely reported that turbulence related to stenosis (narrowing) of arteries creates audible sounds, which may be analyzed to yield information about... Read more
OJEMB, Featured Articles
Temozolomide in Combination With NF-κB Inhibitor Significantly Disrupts the Glioblastoma Multiforme Spheroid Formation
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, accounting for 50% of all cases. GBM patients have a five-year survival rate of merely 5.6% and a median overall survival of 14.6 months with the “Stupp” regimen, 20.9... Read more